ReviewInternational journal of nanomedicine2026
Nano-Enabled Microfluidic Platforms for Functional Immunomonitoring in Pediatric Sepsis.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric sepsis involves dynamic, developmentally conditioned immune dysfunction that a single cytokine concentration or one-time severity label cannot represent. This structured narrative Review examines how nano-enabled microfluidic systems could support blood-sparing, serial assessment of functional immune states in the pediatric intensive care unit (PICU). We separate soluble-protein concentration, cell phenotype, ex vivo stimulation response, cellular effector function, immunometabolic function, and physiology, linking each measurement class to its evidence level and permitted inference. Direct pediatric studies support the biological relevance of longitudinal antigen-presentation, inducible cytokine, lymphocyte, and metabolic readouts, but cohorts remain few, small, and heterogeneous; secondary-infection findings are conflicting. Recent pediatric studies of serial soluble biomarkers and temperature trajectories expand monitoring evidence but do not validate functional immune trajectories. Engineering studies demonstrate nanoscale capture, amplification, transduction, and low-volume processing, including portable multicytokine sensing, yet these Level 4 results do not constitute pediatric clinical validity. We propose a staged sample-to-answer architecture. It distinguishes patient draw from device input, controls stimulation and preanalytics, retains developmental context, and progresses from analytical validation through pediatric feasibility and clinical validity to prospective prediction and decision utility. Artificial intelligence is restricted to age adjustment, longitudinal modeling, multimodal fusion, uncertainty display, and clinician- or nurse-facing visualization. Within the verified accessible corpus through 16 September 2026, no prospectively validated pediatric longitudinal immune-function trajectory model or nano-enabled functional immune assay for immunomodulatory treatment selection was identified. The near-term objective is a verifiable measurement-and-interpretation pathway, not an autonomous treatment selector, tested in multicenter serial cohorts with transparent blood-volume accounting, independent validation, and PICU human-factors evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.